echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > More than 6.5 billion blood lipid-lowering drugs! Yellow Sea Pharmaceuticals is about to be approved.

    More than 6.5 billion blood lipid-lowering drugs! Yellow Sea Pharmaceuticals is about to be approved.

    • Last Update: 2020-09-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network September 1st, recently, Huanghai Pharmaceuticals according to the imitation of 4 categories of reported calcium reschuvastatin tablets (acceptance number CYHS1900180, CYHS1900181) registration status changed to "in approval", is expected to be approved in recent days and treated as reviewed.
    is the first batch of calcium tablets collected, Milnenet data show that in 2019, China's public medical institutions terminal Ruishuvastatin sales of more than 6.5 billion yuan, down 3.52% YoY.
    Reschuvastatin is a selective, competitive HMG-CoA reductase inhibitor, is currently one of the latest statins, because of its strong, fast and safe blood lipid-lowering characteristics, known as "super statin."
    statin calcium tablets originally developed by AstraZenecon, the product named Canding, listed in the United States in 2003 and in China in 2006.
    AstraZenece reported a marked decline in sales since the patent expired in 2016, with global sales of $1,278 million in 2019, down 10.8 percent from a year earlier, and global sales of $583 million from 2020H1, down 10 percent from a year earlier. In 2019, sales of Rishuvastatin at urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) reached more than 6.5 billion yuan, down 3.52% year-on-year, according to
    meters of intranet data.
    , AstraZeneta has a market share of 49.56 per cent, Lunanbet Pharmaceuticals 15.44 per cent and Jingxin Pharmaceuticals 14.12 per cent.
    ruishuvastatin calcium tablets listed on the market application in the review enterprise Ruishuvastatin calcium tablets for the first collection of varieties.
    At present, there are still a number of pharmaceutical companies layout of the product, 13 enterprises submitted a copy of the Rishuvastatin calcium tablets listed application in the review;
    source: MiNet Database, NMPA.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.